Cutaneous reactions to chemotherapy drugs: The art of consultation

Archives of Dermatology

Volumn 139, Issue 1, 2003, Pages 77-81

  Remlinger, Kathleen A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; CORTICOSTEROID; CYCLOSPORIN; CYTARABINE; DACARBAZINE; DACTINOMYCIN; DOCETAXEL; DOXORUBICIN; FLUDARABINE; FLUOROURACIL; HYDROXYUREA; MACROGOL; PENTOSTATIN; THALIDOMIDE; VINCRISTINE SULFATE;

ABSCESS; ACTINIC KERATOSIS; ACUTE GRANULOCYTIC LEUKEMIA; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DERMATOMYOSITIS; ERYTHEMA; ERYTHEMA NODOSUM LEPROSUM; ERYTHRODERMA; EXTRAVASATION; GANGRENE; HIDRADENITIS; HISTOLOGY; HUMAN; HYPEREOSINOPHILIC SYNDROME; HYPERPIGMENTATION; HYPERSENSITIVITY REACTION; LEG ULCER; MEDICAL EDUCATION; MOUTH ULCER; ONYCHOLYSIS; PRESCRIPTION; PRIORITY JOURNAL; PSORIASIS; RAYNAUD PHENOMENON; REVIEW; SCLERODERMA; SICKLE CELL ANEMIA; SKIN ATROPHY; SKIN BIOPSY; SKIN DISCOLORATION; STOMATITIS; TOXIC EPIDERMAL NECROLYSIS;

EID: 0037236045     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.139.1.77     Document Type: Review

References (39)

1. Rabinowitz LG, Cintra ML, Hood AF, Esterly NB. Recurrent palmoplantar hidradenitis in children. Arch Dermatol. 1995;131:817-820.
2. Smith KJ, Skelton HG, James WD, Holland TT, Lupton GP, Angritt P. Neutrophilic eccrine hidradenitis in HIV-infected patients. J Am Acad Dermatol. 1990;23:945-947.
3. Krischer J, Rutschmann O, Roten SV, Harms M, Saurat JH, Pechere M. Neutrophil eccrine hidradenitis in a patient with AIDS. J Dermatol. 1998;25:199-200.
4. Moreno A, Barnadas MA, Ravella A, de Moragas JM. Infectious eccrine hidradenitis in a patient undergoing hemodialysis. Arch Dermatol. 1985;121:1106-1107.
5. Combemale P, Faisant M, Azouley-Petit C, Dupin M, Kanitakis J. Neutrophilic eccrine hidradenitis secondary to infection with Serratia marcescens. Br J Dermatol. 2000;142:784-788.
6. Pierson JC, Helm TN, Taylor JS, Elston DM, Tuthill RJ. Neutrophilic eccrine hidradenitis heralding the onset of acute myelogenous leukemia. Arch Dermatol. 1993;129:791-792.
7. Thorisdottir K, Tomecki KJ, Bergfeld WF, Andresen SW. Neutrophilic eccrine hidradenitis. J Am Acad Dermatol. 1993;28:775-777.
8. Susser WS, Whitaker-Worth DL, Grant-Kels JM. Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol. 1999;40:367-398.
9. Johnson TM, Rapini RP, Duvic M. Inflammation of actinic keratoses from systemic chemotherapy. J Am Acad Dermatol. 1987;17:192-197.
10. DeSpain JD. Dermatologic toxicity of chemotherapy. Semin Oncol. 1992;14:501-507.
11. Fernandez-Obregon AC, Hogan KP, Bibro MK. Flagellate pigmentation from intrapleural bleomycin: a light microscopy and electron microscopy study. J Am Acad Dermatol. 1985;13:464-468.
12. Cortina P, Garrido JA, Tomas JF, Unamuno P, Armijo M. "Flagellate" erythema from bleomycin: with histopathological findings suggestive of inflammatory oncotaxis. Dermatologica. 1990;180:106-109.
13. Rubeiz NG, Salem Z, Dibbs R, Kibbi AG. Bleomycin-induced urticarial flagellate drug hypersensitivity reaction. Int J Dermatol. 1999;38:140-141.
14. Passiu G, Cauli A, Atzeni F, et al. Bleomycin-induced scleroderma: report of a case with a chronic course rather than the typical acute/subacute self-limiting form. Clin Rheumatol. 1999;18:422-424.
15. Surville-Barland J, Caumes E, Ankri A, Frances C, Katlama C, Chosidow O. Blecmycin-induced digital gangrene. Eur J Dermatol. 1998;8:221.
16. Sikic BI. Biochemical and cellular determinants of bleomycin cytotoxicity. Cancer Surv. 1986;5:81-91.
17. Cohen IS, Mosher MB, O'Keefe EJ, Klaus SN, De Conti RC. Cutaneous toxicity of bleomycin therapy. Arch Dermatol. 1973;107:553-555.
18. Yamamoto T, Eckes B, Krieg T. Bleomycin increases steady-state levels of type I collagen, fibronectin and decorin mRNAs in human skin fibroblasts. Arch Dermatol Res. 2000;292:556-561.
19. Kawakami T, Ihn H, Xu W, Smith E, LeRoy C, Trojanowska M. Increased expression of TGF-beta receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-beta signaling to scleroderma phenotype. J Invest Dermatol. 1998;110:47-51.
20. Bennett JP, Burns CP. Absence of progression of recurrent bleomycin skin toxicity without postponement or attenuation of therapy. Am J Med. 1988;85:585-586.
21. Vassallo C, Passamonti F, Merante S, et al. Muco-cutaneous changes during long-term therapy with hydroxyurea in chronic myeloid leukaemia. Clin Exp Dermatol. 2001;26:141-148
22. Daoud MS, Gibson LE, Pittelkow MR. Hydroxyurea dermopathy: a unique lichenoid eruption complicating long-term therapy with hydroxyurea. J Am Acad Dermatol. 1997;36:178-182.
23. Weinlich G, Schuler G, Greil R, Kofler H, Fritsch P. Leg ulcers associated with long-term hydroxyurea therapy. J Am Acad Dermatol. 1998;39:372-374.
24. Varma S, Lanigan SW. Dermatomyositis-like eruption and leg ulceration caused by hydroxyurea in a patient with psoriasis. Clin Exp Dermatol. 1999;24:164-166.
25. Zimmerman GC, Keeling JH, Burris HA, et al. Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent. Arch Dermatol. 1995;131:202-206.
26. Zimmerman GC, Keeling JH, Lowry M, Medina J, Van Hoff DD, Burris HA. Prevention of docetaxel-induced erythrodysesthesia with local hypothermia. J Natl Cancer Inst. 1994;86:557-558.
27. Schrijvers D, Van Den Brande J, Vermorken JB. Supravenous discoloration of the skin due to docetaxel treatment. Br J Dermatol. 2000;142:1069-1070.
28. Correia O, Azevedo C, Pinto Ferreira E, Braga Cruz F, Polonia J. Nail changes secondary to docetaxel (Taxotere). Dermatology. 1999;198:288-290.
29. Vanhooteghem O, Richert B, Vindevoghel A, Vandenbossche L, Vandeveire A, de la Brassinne M. Subungual abscess: a new ungual side-effect related to docetaxel therapy. Br J Dermatol. 2000:143:462-464.
30. Battafarano DF, Zimmerman GC, Older SA, Keeling JH, Burris HA. Docetaxel (Taxotere) associated scleroderma-like changes of the lower extremities: a report of three cases. Cancer. 1995;76:110-115.
31. Lotem M, Hubert A, Lyass O, et al. Skin toxic effects of polyethylene glycolcoated liposomal doxorubicin. Arch Dermatol. 2000;136:1475-1480.
32. Korac B, Buzadzic B. Doxorubicin toxicity to the skin: possibility of protection with antioxidants enriched yeast. J Dermatol Sci. 2001;25:45-52.
33. Chlopkiewicz B, Gruber B. The study on adriamycin induced DNA scissions in human cells with different activity of some antioxidant enzymes. Acta Pol Pharm. 2000;57:359-362.
34. Malkinson FD, Geng L, Hanson WR. Prostaglandins protect against murine hair injury produced by ionizing radiation or doxorubicin. J Invest Dermatol. 1993;101(suppl):135S-137S
35. Lopez AM, Wallace L, Dorr RT, Koff M, Hersh EM, Alberts DS. Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia. Cancer Chemother Pharmacol. 1999;44:303-306.
36. Wolkenstein P, Latarjet J, Roujeau JC, et al. Randomized comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet. 1998;352:1586-1589.
37. Rajkumar SV, Gertz MA, Witzig TE. Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma. N Engl J Med. 2000;343:972-973.
38. Darvay A, Basarab T, Russell-Jones R. Thalidomide-induced toxic pustuloderma. Clin Exp Dermatol. 1997;22:297-299.
39. Davis MDP, Perniciaro C, Dahl PR, Randle HW, McEvoy MT, Leiferman KM. Exaggerated arthropod-bite lesions in patients with chronic lymphocytic leukemia: a clinical, histopathologic, and immunopathologic study of eight patients. J Am Acad Dermatol. 1998;39:27-35.